m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04340)
Name
VPM-4-001
Synonyms
Allogenic LNCaP cell vaccine (prostate tumor), Vakzine Projekt Management; Cell vaccine (prostate cancer), Vakzine Projekt Management; Allogenic LNCaP cells (IL-2, IFN-gamma), Vakzine Projekt Management
    Click to Show/Hide
Status
Preclinical
TTD Drug ID
D0WD6K
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Interferon-gamma (IFNG)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon-gamma (IFNG) is a therapeutic target for VPM-4-001. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VPM-4-001 through regulating the expression of Interferon-gamma (IFNG). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon-gamma (IFNG) is a therapeutic target for VPM-4-001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VPM-4-001 through regulating the expression of Interferon-gamma (IFNG). [1], [2]
References
Ref 1 m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020 Oct 15;39(20):e104514. doi: 10.15252/embj.2020104514. Epub 2020 Sep 23.
Ref 2 CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.